Biocon Pharma Receives Health Canada Approval for Micafungin for Injection
Biocon Pharma Limited, a subsidiary of Biocon Limited, announced on May 11, 2026, that it has secured approval from Health Canada for its product, micafungin for injection, USP. The approved formulations are available in 50 mg and 100 mg strengths.The regulatory approval positions the product for use in a wide range of critical care scenarios involving Candida infections. The drug is indicated for adults and children aged four months and older.
The approved applications for micafungin cover multiple therapeutic areas:
- Treatment: Patients diagnosed with Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses infections.
- Treatment: Patients suffering from esophageal candidiasis.
- Prophylaxis: Preventing Candida infections in patients undergoing hematopoietic stem cell transplantation.
The successful approval further reinforces the strategic strength of Biocon's integrated biosimilars and generics portfolio.
BIOCON Stock Price Movement
Shares of Biocon Limited on Friday slipped by 0.93% to settle at ₹380.4. The stock shed ₹3.55 for the day, finishing after trading on a total volume of 5.68 million shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.